Event coverage ASCO 2018 - Monday 4th June: BMS tries different tack as Mer... Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi
News Puma gains as Roche breast cancer combo disappoints ASCO serves up shock as Roche's data disappoints
News ASCO to shine light on CAR-T developments Kite, Juno, and BlueBird will give updates on T-cell therapies.
Views & Analysis ASCO 2017: Breast cancer next target for Keytruda Immunotherapy combinations will be the focus - but attention is shifting towards these agents proving their overall survival benefits.
Views & Analysis Tunnah’s musings: Lessons for pharma from digital ASCO 2016 Pharma needs to remedy its approach to digital conference engagement.
News Halozyme abandons its €2bn pursuit of Evotec Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
